natgillin/translations-raw huggingface dataset:
Yellowish brown, oval, biconvex film-coated tablets (tablets), engraved with a mark S1 on one side.
Žućkastosmeđe, ovalne, bikonveksne filmom obložene tablete (tablete), s utisnutom oznakom S1 na jednoj strani.
Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with indinavir 800 mg twice daily.
Darunavir: usporedba darunavira/ritonavira 400/100 mg dvaput na dan naspram darunavira/ritonavira 400/100 mg u kombinaciji s indinavirom 800 mg dvaput na dan.
ART-naïve paediatric patients from the age of 12 years to < 18 years, and weighing at least 40 kg DIONE is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with low dose ritonavir in 12 ART-naïve HIV-1 infected paediatric patients aged 12 to less than 18 years and weighing at least 40 kg.
DIONE je otvoreno ispitivanje faze II koje je procijenilo farmakokinetiku, sigurnost, podnošljivost i djelotvornost darunavira s niskom dozom ritonavira u 12 pedijatrijskih bolesnika koji nisu prethodno liječeni ART-om, u dobi od 12 godina do < 18 godina i težine najmanje 40 kg.
Orangish brown, oval, biconvex film-coated tablets, engraved with a mark S2 on one side.
Narančastosmeđe, ovalne, bikonveksne filmom obložene tablete, s utisnutom oznakom S2 na jednoj strani.
The pharmacokinetics of darunavir in combination with ritonavir taken twice daily in 74 treatmentexperienced paediatric patients, aged 6 to 17 years and weighing at least 20 kg, showed that the administered weight-based doses of darunavir/ritonavir resulted in darunavir exposure comparable to that in adults receiving darunavir/ritonavir 600/100 mg twice daily (see section 4.2).
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih dva puta na dan, u 74 prethodno liječena pedijatrijska bolesnika u dobi 6 do 17 godina i težinom najmanje 20 kg, pokazala je da primjena darunavira/ritonavira s doziranjem ovisnim o tjelesnoj težini rezultira izloženošću darunaviru koja je usporediva s onom u odraslih koji primaju darunavir/ritonavir od 600/100 mg dvaput na dan (vidjeti dio 4.2).
Amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine to treat certain heart disorders e.g. abnormal heart beat Lovastatin, simvastatin and lomitapide to lower cholesterol levels Rifampicin to treat some infections such as tuberculosis
liječenje gihta ili obiteljske mediteranske vrućice lurasidon, pimozid, kvetiapin ili sertindol liječenje psihijatrijskih stanja ergot alkaloidi kao što su ergotamin, dihidroergotamin, ergometrin i metilergonovin liječenje migrenskih glavobolja amiodaron, bepridil, dronedaron, ivabradin, kinidin i ranolazin liječenje određenih srčanih poremećaja npr. abnormalni otkucaji srca lovastatin, simvastatin i lomitapid snižavanje razina kolesterola rifampicin liječenje nekih infekcija poput tuberkuloze kombinirani lijek lopinavir/ritonavir ovaj lijek protiv HIV-a pripada istoj skupini kao i Darunavir Krka elbasvir/grazoprevir liječenje infekcije hepatitisom C
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with darunavir coadministered with low dose ritonavir is required.
Ako je potrebno liječenje darunavirom istodobno primjenjenim s niskom dozom ritonavira, preporučuje se smanjiti dozu kolhicina ili prekinuti liječenje kolhicinom u bolesnika s normalnom funkcijom bubrega ili jetre.
Unchanged darunavir accounted for approximately 41.2% and 7.7% of the administered dose in faeces and urine, respectively.
41,2% odnosno 7,7% primijenjene doze darunavira može se naći u stolici, odnosno mokraći u nepromjenjenom obliku.
Rivaroxaban
Rivaroksaban
darunavir/ ritonavir 600/100 mg twice daily N=296
darunavir/ritonavir 600/100 mg dvaput na dan N=296
The Summary of Product Characteristics of ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with darunavir.
Stoga se, prije početka terapije darunavirom, mora pročitati odgovarajući sažetak opisa svojstava za ritonavir.
Dose for adults who have taken antiretroviral medicines before (your doctor will determine this) Maybe you will require a different dose of Darunavir Krka which cannot be administered with these 400 or 800 milligram tablets.
Možda ćete trebati drugačiju dozu lijeka Darunavir Krka koja se ne može primijeniti s ovim tabletama od 400 miligrama ili 800 miligrama.
For dosage recommendations in children see the Summary of Product Characteristics for Darunavir Krka 600 mg tablets.The dose of cobicistat to be used with darunavir has not been established in this patient population.
Za preporučena doziranja u djece, vidjeti sažetak opisa svojstava lijeka za Darunavir Krka 600 mg tablete.
Instructions for children 3 years of age and above, weighing more than 40 kilograms Take 800 milligram Darunavir Krka (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) at the same time, once a day, every day.
Upute za djecu od 3 godine i više, težine najmanje 40 kilograma - Uzmite 800 miligrama lijeka Darunavir Krka (2 tablete koja sadrže
Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration occurs.
Kod istodobne primjene, mora se terapijski pratiti imunosupresivni lijek.
Darunavir is expected to increase these antipsychotic plasma concentrations.
Očekuje se da će darunavir povećati koncentracije tih antipsihotika u plazmi. (CYP3A inhibicija)
Darunavir co-administered with low dose ritonavir and nevirapine can be used without dose adjustments.
Darunavir istodobno primijenjen s niskom dozom ritonavira i nevirapinom može se primijeniti bez prilagodbe doze.
Data based on analyses at week 96
Podaci temeljeni na analizama u 96. tjednu Pripisane vrijednosti izračunate prema TLOVR algoritmu
Concomitant use of darunavir coadministered with low dose ritonavir with lovastatin and simvastatin is therefore contraindicated (see section
Istodobna primjena darunavira primijenjenog istodobno s niskom dozom ritonavira s lovastatinom i simvastatinom je zbog toga kontraindicirana (vidjeti dio 4.3).
HIV-1 RNA < 50 copies/ml CD4+ percent change from baseline CD4+ cell count mean change from baseline ≥ 1.0 log10 decrease from baseline in plasma viral load
Srednja vrijednost promjene broja CD4+ stanica u odnosu na početni ≥ 1,0 log10 sniženje virusnog opterećenja plazme naspram početnih vrijednosti
darunavir/ritonavir 600/100 mg twice daily + OBR N=296
darunavir/ritonavir 600/100 mg dvaput na dan + OBR N=296
When administration of rosuvastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety.
Kada je potrebno primijeniti rosuvastatin i pojačan darunavir, preporučuje se početi s najnižom mogućom dozom rosuvastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
For information on cobicistat, consult the cobicistat Summary of Product Characteristics.
Za informacije o kobicistatu, pročitajte sažetak opisa svojstava lijeka za kobicistat.
Dapoxetine
Paroksetin
Darunavir/ritonavir 800/100 mg once daily + OBR N=294
Ishodi darunavir/ritonavir 800/100 mg jedanput na dan + OBR N=294
When administration of rosuvastatin and darunavir co-administered with low dose ritonavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety.
Kada je potrebno primijeniti rosuvastatin i darunavir primijenjen istodobno s niskom dozom ritonavira, preporučuje se početi s najnižom mogućom dozom rosuvastatina te dozu titrirati do željenog kliničkog učinka i pritom pratiti sigurnost primjene.
cobicistat.
ritonavira.
Co-administration with darunavir coadministered with cobicistat is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena s darunavirom istodobno primijenjenog s kobicistatom (vidjeti dio 4.4).
Yellowish brown, oval, biconvex film-coated tablets, engraved with a mark S1 on one side.
Žućkastosmeđe, ovalne, bikonveksne filmom obložene tablete, s utisnutom oznakom S1 na jednoj strani.
Darunavir with low dose ritonavir may increase the exposure to grazoprevir.
Darunavir s niskom dozom ritonavira može povećati
Boosted darunavir is expected to increase these β-blocker plasma concentrations.
Očekuje se da će pojačan darunavir povećati koncentracije tih β-blokatora u plazmi. (CYP2D6 inhibicija)
The Summary of Product Characteristics of ritonavir must, therefore, be consulted prior to initiation of therapy with darunavir.
Stoga se, prije početka terapije darunavirom, mora pročitati sažetak opisa svojstava lijeka za ritonavir.
With baseline CD4+ cell count <
S početnim brojem CD4+ stanica < 200
600 milligram Darunavir Krka (1 tablet containing 600 milligram of Darunavir Krka) together with 100 milligram ritonavir twice daily.
400 miligrama lijeka Darunavir Krka ili 1 tableta koja sadrži 800 miligrama lijeka Darunavir Krka) zajedno sa 100 miligrama ritnavira jednaput na dan.
Concomitant use of salmeterol and darunavir co-administered with low dose ritonavir may increase plasma
Istodobna primjena salmeterola i darunavira primijenjenog istodobno s niskom dozom ritonavira može povećati koncentracije salmeterola u plazmi.
For further information on cobicistat, consult the cobicistat Summary of Product Characteristics.
Za daljnje informacije o kobicistatu, pogledajte sažetak opisa svojstava lijeka za kobicistat.
The pharmacokinetics of darunavir in combination with ritonavir taken twice daily in 14 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 15 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir /ritonavir 600/100 mg twice daily (see section 4.2).
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih dvaput na dan, u 14 prethodno liječenih pedijatrijskih bolesnika u dobi 3 do < 6 godina s težinom najmanje 15 kg do < 20 kg, pokazala je da doziranje ovisno o tjelesnoj težini rezultira izloženošću darunaviru koja je usporediva s onom u odraslih koji primaju darunavir/ritonavir od 600/100 mg dvaput na dan (vidjeti dio 4.2).
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed under any circumstances if they are receiving Darunavir Krka.
Majke koje primaju lijek Darunavir Krka se mora uputiti da ni pod kojim uvjetima ne doje zbog mogućeg prijenosa virusa HIV-a i zbog mogućih nuspojava u dojene dojenčadi.
Darunavir co-administered with low dose ritonavir and rilpivirine can be used without dose adjustments.
Darunavir istodobno primijenjen s niskom dozom ritonavira i rilpivirinom može se primijeniti bez prilagodbe doze.
Artemether/lumefantrine (a combination medicine to treat malaria) Dasatinib, everolimus,irinotecan,nilotinib, vinblastine, vincristine (to treat cancer) Sildenafil, tadalafil, vardenafil (for erectile dysfunction or to treat a heart and lung disorder called pulmonary arterial hypertension)
Ako se ne mogu primijeniti alternativni lijekovi, ovi lijekovi se smiju primjenjivati samo nakon medicinske procjene te uz pomni liječnički nadzor zbog nuspojava kortikosteroida. - buprenorfin/nalokson (lijekovi za liječenje ovisnosti o opioidima) - salmeterol (lijek za liječenje astme) - artemeter/lumefantrin (kombinirani lijek za liječenje malarije) - dasatinib, everolimus, irinotekan, nilotinib, vinblastin, vinkristin (za liječenje raka) - sildenafil, tadalafil, vardenafil (za liječenje erektilne disfunkcije ili srčanog i plućnog poremećaja koji se naziva plućna arterijska hipertenzija) - glekaprevir/pibrentasvir, simeprevir (za liječenje infekcije hepatitisom C) - fentanil, oksikodon, tramadol (za liječenje boli) - fesoterodin, solifenacin (liječenje poremećaja mokraćnog sustava).
Rare side effects (may affect up to 1 in 1,000 people) a reaction called DRESS [severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung] heart attack, slow heart beating, palpitations visual disturbance chills, feeling abnormal a feeling of confusion or disorientation, altered mood, restlessness fainting, epileptic fits, changes or loss of taste mouth sores, vomiting blood, inflamation of the lips, dry lips, coated tongue running nose skin lesions, dry skin stiffness of muscles or joints, joint pain with or without inflammation changes in some values of your blood cells or chemistry.
- zimica, nenormalno osjećanje - osjećaj smetenosti ili dezorijentacije, promijenjeno raspoloženje, nemir - nesvjestica, epileptički napadaji, promjene ili gubitak okusa - ranice u ustima, povraćanje krvi, upala usnica, suhe usnice, obložen jezik - curenje nosa - oštećenja kože, suha koža - ukočenost mišića ili zglobova, bolovi u zglobovima s ili bez upale - promjene nekih vrijednosti stanica ili kemijskih nalaza u Vašoj krvi.
When administration of pravastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety.
Kada je potrebno primijeniti pravastatin i pojačan darunavir, preporučuje se početi s najnižom mogućom dozom pravastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
Darunavir is expected to increase these antineoplastic plasma
Očekuje se da će darunavir povećati koncentracije tih antineoplastika u plazmi. (CYP3A inhibicija)
Felodipine
Klorazepat
Boosted darunavir and didanosine can be used without dose adjustments.
Pojačan darunavir se može primijeniti s didanozinom bez prilagodbe doze.
Concominant administration of darunavir with low dose ritonavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3).
Istodobna primjena darunavira s niskom dozom ritonavira i lurasidona, pimozida ili sertindola je kontraindicirana (vidjeti dio β-BLOKATORI Karvedilol Metoprolol Timolol
Darunavir co-administered with low dose ritonavir and raltegravir can be used without dose adjustments.
Darunavir istodobno primijenjen s niskom dozom ritonavira i raltegravirom mogu se primijeniti bez prilagodbe doze.
Brownish red, oval, biconvex film-coated tablets (tablets), engraved with a mark S3 on one side.
Smećkastocrvene, ovalne, bikonveksne filmom obložene tablete (tablete), s utisnutom oznakom S3 na jednoj strani.
Outcomes darunavir/ritonavir 600/100 mg twice daily + OBR N=298
Ishodi darunavir/ritonavir 600/100 mg dvaput na dan + OOR N=298
It is not recommended to coadminister darunavir with low dose ritonavir and simeprevir.
Ne preporučuje se istodobna primjena darunavira s niskom dozom ritonavira sa simeprevirom.
Clinical monitoring for central
Neka klinička ispitivanja
administered with darunavir with low dose ritonavir resulting in the potential for increased adverse events usually associated with these agents.
Koncentracije tih lijekova mogu se povećati kada se primjenjuju istodobno s darunavirom s niskom dozom ritonavira rezultirajući potencijalom za povećanje nuspojava obično povezanih s tim lijekovima.
The following patient populations were evaluated (see section 5.1): 80 ART-experienced HIV-1 infected paediatric patients aged from 6 to 17 years and weighing at least 20 kg who received darunavir tablets with low dose ritonavir twice daily in combination with other antiretroviral agents.
- 80 pedijatrijskih bolesnika u dobi od 6 do 17 godina i težine najmanje 20kg, prethodno liječenih ART-om, a inficirani su virusom HIV-1 te su primali darunavir tablete s niskom dozom ritonavira dvaput na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
Boosted darunavir is expected to increase these antineoplastic plasma concentrations.
Očekuje se da će pojačan darunavir povećati koncentracije tih antineoplastika u plazmi. (CYP3A inhibicija)
Darunavir co-administered with low dose ritonavir can be expected to increase the plasma concentrations of calcium channel blockers.
Felodipin Nikardipin Nifedipin Verapamil dozom ritonavira može se očekivati da povisi koncentracije blokatora kalcijevih kanala u plazmi. (inhibicija CYP3A i/ili CYP2D6)
Co-administration of boosted darunavir and alfuzosin is contraindicated (see section 4.3).
Istodobna primjena pojačang darunavira s alfuzozinom je kontraindicirana (vidjeti dio 4.3).
The recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food.
Odrasli bolesnici prethodno liječeni antiretrovirusnom terapijom (ART-om) Preporučeni režim doziranja je 600 mg dvaput na dan uz 100 mg ritonavira dvaput na dan uzeto s hranom.
rifabutin Cmax darunavir AUC ↑ 53% darunavir Cmin ↑ 68% darunavir Cmax ↑ 39% sum of active moieties of rifabutin (parent drug + 25-O-desacetyl metabolite) The interaction trial showed a comparable daily systemic exposure for rifabutin between treatment at 300 mg once daily alone and 150 mg once every other day in combination with darunavir/ritonavir (600/100 mg twice daily) with an about 10fold increase in the daily exposure to the active metabolite 25-O-desacetylrifabutin.
Simeprevir simeprevir AUC ↑ 159% simeprevir Cmin ↑ 358% simeprevir Cmax ↑ 79% darunavir AUC ↑ 18% darunavir Cmin ↑ 31% darunavir Cmax ↔ Doza simeprevira u ovom ispitivanju interakcija bila je 50 mg kada se istodobno primjenjivao u kombinaciji s darunavirom/ritonavirom, u usporedbi sa 150 mg u skupini liječenoj samim simeprevirom.
No dose adjustment is required for darunavir/ritonavir during pregnancy and postpartum.
Tijekom trudnoće i postpartalnog razdoblja prilagodba doze darunavira/ritonavira nije potrebna.
When administration of pravastatin and darunavir co-administered with low dose ritonavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety.
Kada je potrebno primijeniti pravastatin i darunavir primijenjen istodobno s niskom dozom ritonavira, preporučuje se početi s najnižom mogućom dozom pravastatina te dozu titrirati do željenog kliničkog učinka i pritom pratiti sigurnost primjene.
Outcomes darunavir/ ritonavir 800/100 mg once daily N=343
TITAN 48. tjedan darunavir/ritonavir 800/100 mg jedanput na dan N=343
If efavirenz is to be used in combination with darunavir /ritonavir, the darunavir/ritonavir
TITAN 48. tjedan darunavir/ritonavi
Darunavir co-administered with low dose ritonavir and didanosine can be used without dose adjustments.
Darunavir se može istodobno primijeniti s niskom dozom ritonavira i didanozinom bez prilagodbe doze.
St John's wort is expected to decrease the plasma concentrations of darunavir or its pharmacoenhancers.
Za gospinu travu se očekuje da snizi koncentracije darunavira ili njegovih farmakokinetičkih pojačivača u plazmi. (indukcija CYP450)
St John's wort is expected to decrease the plasma concentrations of darunavir and ritonavir.
Za gospinu travu se očekuje da snizi koncentracije darunavira i ritonavira u plazmi. (indukcija CYP450)
The Summary of Product Characteristics of cobicistat or ritonaviras appropriate, must therefore be consulted prior to initiation of therapy with darunavir.
Stoga se, prije početka terapije darunavirom mora pročitati odgovarajući sažetak opisa svojstava lijeka za kobicistat ili ritonavir.
Film coating:
Film ovojnica tablete:
Triazolam and oral (taken by mouth) midazolam to help you sleep and/or relieve anxiety
Svrha uzimanja lijeka avanafil liječenje erektilne disfunkcije astemizol ili terfenadin liječenje simptoma alergije triazolam i oralni (uzima se kroz usta) midazolam pomaže Vam spavati i/ili ublažava tjeskobu cisaprid liječenje nekih stanja želuca kolhicin (ako imate tegobe s bubregom i/ili jetrom)
Crospovidone
Vinkristin
KRKA Pharma Dublin, Ltd. Tel: + 353 1 293 91 80
KRKA Farmacéutica, S.L. Tel: + 34 911 61 03 81
KI.PA.
- proljev.
Rifampicin to treat some infections such as tuberculosis
LIJEKOVI ZA LIJEČENJE INFEKCIJA MIKOBAKTERIJAMA
The combination of rifampicin and boosted darunavir is contraindicated (see section 4.3).
Kombinacija rifampicina i pojačanog darunavira je kontraindicirana (vidjeti dio
Brownish red, oval, biconvex film-coated tablets, engraved with a mark S3 on one side.
Smećkastocrvene, ovalne, bikonveksne filmom obložene tablete, s utisnutom oznakom S3 na jednoj strani.
This can be seen in a blood test. high blood pressure, flushing red or dry eyes fever, swelling of lower limbs due to fluids, malaise, irritability, pain symptoms of infection, herpes simplex erectile dysfunction, enlargement of breasts sleeping problems, sleepiness, depression, anxiety, abnormal dreams, decrease in sexual drive
ekcem, prekomjerno znojenje, noćno znojenje, gubitak kose, akne, ljuskasta koža, obojenje noktiju - bolovi u mišićima, grčevi u mišićima ili slabost, bolovi u udovima, osteoporoza - usporavanje funkcije štitnjače, može se vidjeti iz rezultata krvnih pretraga - povišeni krvni tlak, naleti vrućine - crvene ili suhe oči - vrućica, oticanje nogu zbog nakupljanja tekućine, opća slabost, razdražljivost,
NC=F
Tip C
Vardenafil darunavir and low dose ritonavir.
Kombinacija avanafila i darunavira s niskom dozom
Methadone (to treat opiate dependance)
- metformin (za liječenje šećerne bolesti tipa 2).
Boosted darunavir is expected to increase these antipsychotic plasma concentrations.
Očekuje se da će pojačan darunavir povećati koncentracije tih antipsihotika u plazmi. (CYP3A inhibicija)
If you take more Darunavir Krka than you should Contact your doctor, pharmacist or nurse immediately.
Odmah kontaktirajte svog liječnika, ljekarnika ili medicinsku sestru.
Dose for children of 3 years of age and above, weighing at least 15 kilograms who have taken antiretroviral medicines before (your child's doctor will determine this) The doctor will work out the right dose based on the weight of the child (see table below).
Doza za djecu u dobi od 3 godine starosti i više, težine najmanje 15 kilograma koja su prethodno uzimala antiretrovirusne lijekove (to će odrediti liječnik Vašeg djeteta)
Careful patient monitoring and dose adjustment of metformin is recommended in patients who are taking darunavir co-administered with cobicistat.
U bolesnika koji uzimaju darunavir istodobno primijenjen s kobicistatom, preporučuje se pažljivo praćenje bolesnika i prilagodba doze metformina (nije primjenjivo na darunavir istodobno primijenjen s ritonavirom)
Concentrate for solution for injection
Veličina pakovanja koncentrat za otopinu za injekciju otopina za injekciju
Komárom, 2900 Hungary
Komárom, 2900 Mađarska
2 Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors.
2 U većine bolesnika u kojih su prijavljeni ovi događaji već su postojali kardiovaskularni faktori rizika.
Severe hypotension (< 90/50 mm Hg).
Teška hipotenzija (< 90/50 mmHg).
If you have taken or are planning to take Talmanco, avoid excessive drinking (over 5 units of alcohol), since this may increase the risk of dizziness when standing up.
Ako ste uzeli ili planirate uzeti Talmanco, izbjegavajte prekomjernu konzumaciju alkohola (više od 5 jedinica alkohola), jer to može povećati rizik od omaglice pri ustajanju.
Across all clinical studies, reports of changes in colour vision were rare (< 0.1%).
U svim su kliničkim ispitivanjima izvješća o promjenama u raspoznavanju boja bila rijetka (< 0,1%).
If you stop taking Talmanco Do not stop taking your tablets, unless advised otherwise by your doctor.
Ako prestanete uzimati Talmanco Nemojte prestati uzimati tablete, osim ako Vam liječnik nije savjetovao drugačije.
Do not take this medicine when pregnant, unless it is strictly necessary and you have discussed this with your doctor.
Nemojte uzimati ovaj lijek u trudnoći, osim ako je to nužno potrebno i ako ste o tome razgovarali sa svojim liječnikom.
Children and adolescents This medicine is not indicated for use by children and adolescents under the age of 18.
Ovaj lijek nije namijenjen za primjenu u djece i adolescenata mlađih od 18 godina.
Other medicines and Talmanco
Drugi lijekovi i Talmanco